Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
GNLX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: June 01, 2026
Report Source: 2026 1st Quarter Report
Genelux Corp. Stock Analysis GNLX
United States Health Care Micro Cap Report: Genelux Corp. manufactures and markets drugs and virus strains solutions. The company is headquartered in Westlake Village, California and currently employs 25 full-time employees. The company went IPO on 2023-01-26. The firm is focused on developing a pipeline of next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its clinical and preclinical product candidates are intended to selectively kill tumor cells and induce a robust immune response against a patient’s tumor neoantigens. Its product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus (VACV), a stable deoxyribonucleic acid (DNA) virus with a large engineering capacity. Olvi-Vec is developed for the treatment of multiple cancers based on the results of preclinical studies that suggest Olvi-Vec has the potential to infect and directly kill a wide range of tumor cell types in vitro and in vivo and produce an anti-tumor immune response. Its portfolio also include oncolytic vaccinia immunotherapy clinical candidates.
Read More Genelux Corp (GNLX) Chart
Key Statistics of Genelux Corp (GNLX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$2.87Volume
91.82KP/E Ratio (TTM)
-52 Week Range
Market Cap
130.93MAvg. Volume
174.22KDividend Yield
-Financial Metrics & Statements of Genelux Corp (GNLX)
FAQ's for Genelux Corp (GNLX)
- According to Musaffa’s Shariah screening methodology, Genelux Corp (GNLX) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Genelux Corp using these criteria to determine its compliance status.
- Muslim investors may consider investing in Genelux Corp if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Genelux Corp by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Genelux Corp may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Genelux Corp on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.